Extensive psoriasis induced by pegylated interferon: a case report.

Area of Science:

• Hepatology
• Dermatology
• Pharmacology

Background:

• Chronic hepatitis C (HCV) treatment can be challenging, especially in non-responders to previous therapies.
• Interferon-based regimens remain a cornerstone for HCV management, though side effects are common.

Purpose of the Study:

• To describe the clinical course of a treatment-resistant chronic hepatitis C patient.
• To document the efficacy and adverse event profile of Pegylated Interferon plus Ribavirin therapy.
• To report on the management and resolution of therapy-induced psoriasis.

Main Methods:

• A 50-year-old female patient with chronic hepatitis C (genotype 2a/2c) received Pegylated Interferon alpha2b plus Ribavirin for 24 weeks.
• Clinical and virological parameters were monitored throughout the treatment course.
• Cutaneous side effects, specifically psoriasis, were observed and documented.

Main Results:

• The patient achieved normalization of transaminase levels by month four and sustained HCV-RNA negativity by month five.
• A significant, albeit temporary, psoriasis exacerbation occurred during treatment, affecting over 75% of the body surface area.
• Hepatitis C resolved, and psoriasis spontaneously receded completely one month after therapy cessation.

Conclusions:

• Pegylated Interferon plus Ribavirin can be effective in treatment-experienced chronic hepatitis C patients.
• Therapy-induced psoriasis, while potentially severe, may be transient and resolve post-treatment.
• Close monitoring of both hepatic and dermatological parameters is crucial during antiviral therapy.